Psoriatic Arthritis - Hand

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy affecting 5 to 10 percent of patients with psoriasis. Hand involvement occurs in approximately 70 percent of PsA patients and often determines functional capacity and quality of life. The disease exhibits unique patterns of joint destruction that differ fundamentally from rheumatoid arthritis, requiring distinct surgical strategies.

The hand surgeon must recognize five distinct clinical patterns, understand the impact of disease-modifying medications on surgical outcomes, and coordinate perioperative management with rheumatology. Surgical decision-making balances aggressive disease progression against modern biologic therapy efficacy.

Inflammatory Pathways

Psoriatic arthritis is driven by dysregulated immune pathways involving TNF-alpha, IL-17, and IL-23. Unlike rheumatoid arthritis where synovitis predominates, enthesitis (inflammation at tendon insertions) is the hallmark of PsA. The close anatomical relationship between the nail matrix and DIP joint explains the strong correlation between nail disease and DIP arthritis.

Key Pathophysiologic Features:

• Enthesitis: Primary pathology at tendon insertions
• Osteoproliferation AND erosion: Unique combination vs pure erosion in RA
• HLA associations: HLA-B27 (spondylitis), HLA-Cw6 (skin)
• Cytokine pathways: TNF-alpha, IL-17, IL-23 targeted by biologics

Psoriatic arthritis is a seronegative spondyloarthropathy affecting 5-10% of psoriasis patients, with hand involvement in 70%. Diagnosis uses CASPAR criteria (91.4% sensitivity, 98.7% specificity): psoriasis history, nail dystrophy, negative RF, dactylitis, and juxta-articular new bone formation. Classic radiographic finding is "pencil-in-cup" deformity at DIPs. Five clinical patterns exist: SADDS - Symmetric polyarticular (RA-like), Asymmetric oligoarticular (most common), DIP predominant, Destructive (arthritis mutilans), Spondylitis. Dactylitis (sausage digit) is pathognomonic, representing tenosynovitis plus joint inflammation. Nail changes correlate with DIP severity. Unlike RA, synovectomy has limited role due to aggressive bone erosion.

Asymmetric Oligoarticular Pattern

The most common presentation involves fewer than five joints in an asymmetric distribution. Ray pattern involvement is characteristic, where multiple joints in one digit are affected while adjacent digits remain normal. This pattern responds well to local corticosteroid injection and targeted DMARDs.

Clinical Features:

• 1-4 joints affected
• Ray distribution common
• Dactylitis frequent (sausage digit)
• Better functional prognosis
• May progress to polyarticular pattern in 25 percent

Symmetric Polyarticular Pattern

Mimics rheumatoid arthritis but includes DIP joints. This pattern presents the greatest diagnostic challenge and accounts for 30 to 40 percent of PsA cases. Functional impairment parallels rheumatoid arthritis severity.

Distinguishing Features from RA:

• DIP joint involvement
• Asymmetric severity despite symmetric distribution
• Absence of rheumatoid nodules
• Radiographic new bone formation
• Nail changes in 80 percent

DIP Predominant Pattern

Classic psoriatic arthritis pattern with isolated DIP involvement. Strong correlation exists between nail psoriasis and underlying DIP arthritis. This pattern often progresses slowly but can develop severe destructive changes.

Surgical Considerations:

• Arthrodesis gold standard
• Arthroplasty contraindicated in active disease
• Nail bed involvement complicates wound healing
• Mucous cyst association
• Consider MCP or PIP involvement before isolated DIP fusion

Arthritis Mutilans

The most destructive pattern features telescoping digits from severe osteolysis. Modern biologic therapy has reduced prevalence from 16 percent to approximately 5 percent. Surgical reconstruction remains challenging.

Reconstruction Options:

• Ray resection (most reliable)
• Arthrodesis with bone grafting
• Tendon transfers for extension loss
• Wrist fusion for stability
• Consider prosthetic digits for severe cases

CASPAR Criteria

The Classification Criteria for Psoriatic Arthritis (CASPAR) provides standardized diagnosis with high sensitivity and specificity. A score of 3 or more indicates psoriatic arthritis.

Radiographic Assessment

Plain radiographs demonstrate characteristic features that distinguish PsA from rheumatoid arthritis. The combination of erosive changes AND new bone formation is pathognomonic.

Grading Radiographic Severity:

• Grade 1: Soft tissue swelling, periarticular osteopenia
• Grade 2: Joint space narrowing, small erosions
• Grade 3: Multiple erosions, subluxation, periostitis
• Grade 4: Arthritis mutilans, telescoping, ankylosis

Laboratory Studies

Unlike rheumatoid arthritis, laboratory findings in PsA are relatively nonspecific. The diagnosis relies primarily on clinical and radiographic features.

Key Laboratory Features:

• Rheumatoid factor: Negative (positive in less than 10 percent)
• Anti-CCP antibodies: Negative
• HLA-B27: Positive in 20 percent (50 percent with spondylitis)
• ESR/CRP: Elevated in 50 percent
• Uric acid: Check to exclude gout
• ANA: May be weakly positive

Modern biologic therapy has revolutionized PsA treatment but creates perioperative management challenges. Understanding drug mechanisms and half-lives is essential for surgical planning.

Indications for Surgery

Surgical intervention in PsA serves distinct purposes compared to rheumatoid arthritis. The aggressive bone destruction and less prominent synovitis alter the risk-benefit calculation.

Primary Indications:

• Pain refractory to medical management (6 months optimized therapy)
• Progressive deformity affecting function
• Tendon rupture or impending rupture
• Joint instability limiting ADLs
• Arthritis mutilans salvage
• Neurologic compromise (rare)

Relative Contraindications:

• Active skin psoriasis over surgical field
• Uncontrolled systemic disease
• Recent biologic dose (within half-life)
• Poor medical optimization
• Unrealistic patient expectations

Synovectomy

Unlike rheumatoid arthritis where early synovectomy prevents erosions, PsA synovectomy has limited disease-modifying effect. Bone destruction predominates over synovial inflammation.

Arthrodesis

Joint fusion represents the gold standard for end-stage PsA arthritis in the hand. The aggressive bone destruction makes arthroplasty less reliable.

Arthroplasty

Joint replacement in PsA carries higher failure rates than in osteoarthritis due to ongoing inflammation and bone quality issues. Patient selection is critical.

Arthroplasty Considerations:

• Silicone MCP arthroplasty: 30-40% failure at 10 years in PsA (vs 15% in RA)
• PIP arthroplasty: Very limited role, consider fusion instead
• CMC arthroplasty: Acceptable outcomes for thumb base arthritis
• Wrist arthroplasty: Contraindicated in PsA due to bone quality

Prerequisites for Arthroplasty:

• Quiescent disease on stable medical therapy
• Adequate bone stock
• Intact soft tissue envelope
• No active skin psoriasis
• Realistic expectations
• Compliance with therapy

The most severe PsA pattern requires specialized reconstructive approach. Modern biologics have reduced prevalence but surgical salvage remains necessary.

Ray Resection

Removal of severely destroyed rays improves function by eliminating painful unstable digits and narrowing hand for better grip.

Indications:

• Telescoping digit with bone loss exceeding 50 percent
• Loss of extensor function
• Painful unstable digit interfering with function
• Patient preference after understanding alternatives

Technique:

• Ray resection at metacarpal base
• Preserve thumb, index, long when possible
• Address adjacent metacarpals to narrow hand
• Reconstruct first web space
• Intrinsic muscle balancing

Functional Outcomes:

• Pain relief: 85-90%
• Improved grip: 60-70%
• Patient satisfaction: 70-80%
• Return to ADLs: Variable

Arthrodesis with Bone Grafting

Attempted salvage of ray with structural bone graft and rigid fixation. Technically demanding with unpredictable outcomes.

Indications:

• Key digit (thumb, index, long)
• Patient motivated for staged reconstruction
• Adequate soft tissue envelope
• Good medical control

Technique:

• Structural iliac crest graft
• Rigid plate or external fixation
• Prolonged protected mobilization
• Consider BMP augmentation

Outcomes:

• Union rate: 60-70% (lower than standard arthrodesis)
• Requires prolonged immobilization
• Staged procedures common
• Better for thumb than fingers

Enthesitis represents a hallmark PsA feature affecting tendon insertions. Flexor tenosynovitis contributes to dactylitis.

Flexor Tenosynovitis and Trigger Digits

Inflammatory tenosynovitis causes triggering and contributes to sausage digit appearance. Treatment parallels idiopathic trigger finger but with higher recurrence.

Clinical Features:

• Diffuse tendon sheath swelling
• Triggering at A1 pulley
• Dactylitis when combined with joint synovitis
• May affect multiple digits

Non-operative Management:

• Optimize systemic therapy
• Corticosteroid injection (60-70% success)
• Splinting
• Activity modification

Surgical Release:

• Standard A1 pulley release
• Extended tenosynovectomy if needed
• Higher recurrence than idiopathic (20% vs 5%)
• Resume biologics when wound healed

Extensor Tendon Rupture

Less common than in rheumatoid arthritis but occurs from dorsal erosions and synovitis. EDC ruptures most frequent.

Risk Factors:

• Dorsal wrist synovitis
• Carpal bone erosions
• Lister tubercle destruction
• Failed medical therapy

Management:

• EIP to EPL transfer (EPL rupture)
• Side-to-side repair (single EDC)
• Tendon graft (chronic, retracted)
• Address underlying bony prominences

Coordinated care with rheumatology optimizes outcomes and minimizes complications. Document comprehensive perioperative plan.

Preoperative Optimization

Medical Optimization:

• Rheumatology clearance documented
• Biologic holding strategy confirmed
• Diabetes control (HbA1c less than 7.5%)
• Nutrition assessment (albumin greater than 3.5 g/dL)
• Smoking cessation 4 weeks minimum

Skin Assessment:

• Active psoriasis over surgical field: Consider treatment delay
• Chronic plaque psoriasis: Acceptable if quiescent
• Pustular psoriasis: Defer surgery
• Document lesions with photographs

Medication Management:

• Hold biologics per agent half-life
• Continue methotrexate
• Reduce corticosteroids to less than 10 mg prednisone equivalent
• Resume NSAIDs 24 hours post-op
• Plan biologic resumption (typically 14 days)

Intraoperative Considerations

Anesthesia:

• Regional anesthesia preferred (shorter PACU time)
• Avoid general anesthesia if C-spine involvement
• Document airway assessment

Surgical Technique:

• Atraumatic tissue handling (friable skin)
• Adequate debridement of devitalized bone
• Rigid fixation for fusions
• Meticulous hemostasis
• Consider negative pressure wound therapy for high-risk wounds

Antibiotic Prophylaxis:

• Standard cefazolin dosing
• Vancomycin if MRSA risk
• Extended prophylaxis not indicated
• Document allergy status

Postoperative Care

Wound Management:

• Inspect at 5-7 days (earlier if concerns)
• Negative pressure therapy for high-risk wounds
• Extended antibiotics NOT routine
• Early detection of infection critical

Rehabilitation:

• Protected mobilization per procedure
• Hand therapy when stable
• Gradual strengthening
• Monitor for flare

Medical Therapy Resumption:

• Methotrexate: Continue throughout
• Biologics: Resume when wound sealed (typically 14 days)
• Corticosteroids: Taper to baseline
• NSAIDs: Resume 24 hours post-op

Functional Outcomes

Modern biologic therapy combined with appropriate surgical intervention improves long-term outcomes compared to historical cohorts.

Surgical Outcome Factors:

• Arthrodesis: 85-95% union, 90% pain relief
• Synovectomy: 60-70% good results at 2 years
• Arthroplasty: 70-80% survival at 10 years (inferior to OA)
• Tendon surgery: Comparable to idiopathic if disease controlled

Complications

General Complications:

• Infection: 2-5% (higher with biologics)
• Wound healing problems: 5-10% (psoriatic skin)
• Disease flare: 10-15% perioperatively
• Stiffness: 10-20%

Procedure-Specific:

• Fusion nonunion: 5-15%
• Fusion malunion: 5-10%
• Arthroplasty loosening: 20-30% at 10 years
• Implant fracture: 5%

Long-term Disease Progression

Even with optimal medical and surgical therapy, PsA demonstrates progressive course in subset of patients.

Predictors of Progressive Disease:

• Polyarticular onset
• Elevated inflammatory markers
• Early radiographic erosions
• Arthritis mutilans pattern
• Inadequate response to biologics

Monitoring:

• Clinical examination every 3-6 months
• Radiographs annually or with symptoms
• Functional assessment (DASH, MHQ)
• Rheumatology co-management
• Adjust therapy based on progression

The DIP-predominant, asymmetric, seronegative pattern with nail change distinguishes PsA from the other common inflammatory and degenerative hand arthropathies. The single highest-yield discriminator versus rheumatoid arthritis is the combination of DIP involvement and juxta-articular new bone formation.

Algorithm

View larger

Medical therapy is rheumatology-led and disease-modifying; surgery treats the mechanical consequences of established structural damage. Key surgical-planning principles unique to PsA:

• Stage by symptom and biomechanics: address the most symptomatic joint first; DIP fusion often stabilises a secondary PIP swan-neck by restoring extensor balance, so re-assess the PIP before committing to a second fusion.
• Respect the skin: never incise through active plaques; the Koebner phenomenon can flare psoriasis along the wound. Optimise skin disease with dermatology first.
• Coordinate biologic timing with the prescribing rheumatologist - continue methotrexate, withhold biologics over the surgical window, and resume once the wound has healed.

Surgical PsA evidence is dominated by small retrospective series; no randomised trials compare hand reconstruction techniques in this population. The main unresolved questions:

• Optimal biologic washout duration: society guidance (ACR/AAHKS) is based on low- to moderate-quality evidence and recommends operating at the end of the dosing cycle rather than a fixed number of weeks. The true infection trade-off for hand surgery specifically is unquantified, and flare risk from prolonged withdrawal must be weighed against a modest infection signal.
• Arthrodesis versus arthroplasty: fusion is favoured because of aggressive erosive bone loss and poor implant survival, but pyrocarbon and surface-replacement implants have not been studied with adequate follow-up in PsA, so the boundary for joint-preserving replacement remains opinion-based.
• Role of synovectomy: unlike rheumatoid arthritis, synovectomy is not disease-modifying in PsA because bone destruction, not synovial pannus, predominates; its value beyond temporary symptom relief is debated.
• Surgery in the biologic era: widespread early biologic therapy has reduced arthritis mutilans and severe erosive hand disease, shifting the surgical caseload toward lower-grade deformity - but long-term data on whether this durably prevents the need for hand surgery are still maturing.
• Timing of skin optimisation: how quiescent psoriasis must be over the surgical field to avoid the Koebner phenomenon is not defined by trial evidence.

Psoriatic arthritis affects roughly 0.1 to 0.25 percent of the general population worldwide, occurring in 6 to 25 percent of people with psoriasis depending on ascertainment. Prevalence is highest in populations of European descent and lower in East Asian and sub-Saharan African populations. Onset typically falls between 30 and 50 years with an approximately equal sex ratio. Hand and other peripheral joint involvement dominates the disease burden globally.

Registry and Resource Considerations

• Registries: National biologics registries (BSRBR-RA/UK, DANBIO/Denmark, ATTRA/Czech, CORRONA/US) track drug survival, infection and malignancy signals for the bDMARDs used in PsA; dedicated hand-implant registry data in PsA are sparse, so survivorship is extrapolated from rheumatoid and osteoarthritis small-joint series.
• High-resource settings: Early biologic access has reduced the incidence of arthritis mutilans and severe erosive hand disease; small-joint arthrodesis with rigid internal fixation and hand therapy is standard.
• Limited-resource settings: Restricted biologic availability means more advanced erosive presentations; methotrexate remains the backbone, and K-wire arthrodesis or ray resection are pragmatic, low-cost reconstructive options where implants and theatre access are constrained.

Psoriatic arthritis of the hand presents unique diagnostic and therapeutic challenges. The disease exhibits five distinct clinical patterns with DIP predominance distinguishing it from rheumatoid arthritis. Diagnosis relies on CASPAR criteria with pathognomonic pencil-in-cup radiographic deformity.

Modern biologic therapy has revolutionized disease management, reducing arthritis mutilans prevalence and delaying surgical intervention. When surgery is required, arthrodesis provides more reliable outcomes than arthroplasty due to aggressive bone destruction. Coordination with rheumatology for perioperative biologic management is essential.

The hand surgeon must recognize the limited role of synovectomy compared to RA, understand appropriate fusion positioning, and master salvage techniques including ray resection for arthritis mutilans. Patient selection, realistic expectations, and optimization of medical therapy determine outcomes in this challenging condition.